OBJECTIVE: To compare clinical, imaging, and neuropsychological characteristics and longitudinal course of subjects with pre-mild cognitive impairment (pre-MCI), who exhibit features of MCI on clinical examination but lack impairment on neuropsychological examination, to subjects with no cognitive impairment (NCI), nonamnestic MCI (naMCI), amnestic MCI (aMCI), and mild dementia. METHODS: For 369 subjects, clinical dementia rating sum of boxes (CDR-SB), ApoE genotyping, cardiovascular risk factors, parkinsonism (UPDRS) scores, structural brain MRIs, and neuropsychological testing were obtained at baseline, whereas 275 of these subjects received an annual follow-up for 2-3 years. RESULTS: At baseline, pre-MCI subjects showed impairment on tests of executive function and language, higher apathy scores, and lower left hippocampal volumes (HPCV) in comparison to NCI subjects. Pre-MCI subjects showed less impairment on at least one memory measure, CDR-SB and UPDRS scores, in comparison to naMCI, aMCI and mild dementia subjects. Follow-up over 2-3 years showed 28.6% of pre-MCI subjects, but less than 5% of NCI subjects progressed to MCI or dementia. Progression rates to dementia were equivalent between naMCI (22.2%) and aMCI (34.5%) groups, but greater than for the pre-MCI group (2.4%). Progression to dementia was best predicted by the CDR-SB, a list learning and executive function test. CONCLUSION: This study demonstrates that clinically defined pre-MCI has cognitive, functional, motor, behavioral and imaging features that are intermediate between NCI and MCI states at baseline. Pre-MCI subjects showed accelerated rates of progression to MCI as compared to NCI subjects, but slower rates of progression to dementia than MCI subjects.
OBJECTIVE: To compare clinical, imaging, and neuropsychological characteristics and longitudinal course of subjects with pre-mild cognitive impairment (pre-MCI), who exhibit features of MCI on clinical examination but lack impairment on neuropsychological examination, to subjects with no cognitive impairment (NCI), nonamnestic MCI (naMCI), amnestic MCI (aMCI), and mild dementia. METHODS: For 369 subjects, clinical dementia rating sum of boxes (CDR-SB), ApoE genotyping, cardiovascular risk factors, parkinsonism (UPDRS) scores, structural brain MRIs, and neuropsychological testing were obtained at baseline, whereas 275 of these subjects received an annual follow-up for 2-3 years. RESULTS: At baseline, pre-MCI subjects showed impairment on tests of executive function and language, higher apathy scores, and lower left hippocampal volumes (HPCV) in comparison to NCI subjects. Pre-MCI subjects showed less impairment on at least one memory measure, CDR-SB and UPDRS scores, in comparison to naMCI, aMCI and mild dementia subjects. Follow-up over 2-3 years showed 28.6% of pre-MCI subjects, but less than 5% of NCI subjects progressed to MCI or dementia. Progression rates to dementia were equivalent between naMCI (22.2%) and aMCI (34.5%) groups, but greater than for the pre-MCI group (2.4%). Progression to dementia was best predicted by the CDR-SB, a list learning and executive function test. CONCLUSION: This study demonstrates that clinically defined pre-MCI has cognitive, functional, motor, behavioral and imaging features that are intermediate between NCI and MCI states at baseline. Pre-MCI subjects showed accelerated rates of progression to MCI as compared to NCI subjects, but slower rates of progression to dementia than MCI subjects.
Authors: M A Mintun; G N Larossa; Y I Sheline; C S Dence; S Y Lee; R H Mach; W E Klunk; C A Mathis; S T DeKosky; J C Morris Journal: Neurology Date: 2006-08-08 Impact factor: 9.910
Authors: David A Loewenstein; Amarilis Acevedo; Raymond Ownby; Joscelyn Agron; Warren W Barker; Richard Isaacson; Silvia Strauman; Ranjan Duara Journal: Am J Geriatr Psychiatry Date: 2006-11 Impact factor: 4.105
Authors: P Fischer; S Jungwirth; S Zehetmayer; S Weissgram; S Hoenigschnabl; E Gelpi; W Krampla; K H Tragl Journal: Neurology Date: 2007-01-23 Impact factor: 9.910
Authors: Ranjan Duara; David A Loewenstein; Maria Greig; Amarilis Acevedo; Elizabeth Potter; Jason Appel; Ashok Raj; John Schinka; Elizabeth Schofield; Warren Barker; Yougui Wu; Huntington Potter Journal: Am J Geriatr Psychiatry Date: 2010-04 Impact factor: 4.105
Authors: Li Wang; Gerald van Belle; Paul K Crane; Walter A Kukull; James D Bowen; Wayne C McCormick; Eric B Larson Journal: J Am Geriatr Soc Date: 2004-12 Impact factor: 5.562
Authors: Henry M Olivera-Perez; Larry Lam; Johnny Dang; Weilan Jiang; Fabian Rodriguez; Elizabeth Rigali; Sarah Weitzman; Verna Porter; Liudmilla Rubbi; Marco Morselli; Matteo Pellegrini; Milan Fiala Journal: FASEB J Date: 2017-06-20 Impact factor: 5.191
Authors: Priya Palta; Sherita Hill Golden; Jeanne A Teresi; Walter Palmas; Paula Trief; Ruth S Weinstock; Steven Shea; Jennifer J Manly; Jose A Luchsinger Journal: J Diabetes Complications Date: 2014-07-01 Impact factor: 2.852
Authors: Nancy J Donovan; Rebecca E Amariglio; Amy S Zoller; Rebecca K Rudel; Teresa Gomez-Isla; Deborah Blacker; Bradley T Hyman; Joseph J Locascio; Keith A Johnson; Reisa A Sperling; Gad A Marshall; Dorene M Rentz Journal: Am J Geriatr Psychiatry Date: 2014-02-26 Impact factor: 4.105
Authors: Leslie S Gaynor; Rosie E Curiel Cid; Ailyn Penate; Mónica Rosselli; Sara N Burke; Meredith Wicklund; David A Loewenstein; Russell M Bauer Journal: J Int Neuropsychol Soc Date: 2019-08 Impact factor: 2.892